Skip to content
Calculator
Fact-check

Podcast peptide claims, fact-checked

Last updated: November 4, 2026 · 8 min read · By the Grey Peptides Editorial Board

Microphones and headphones on a table in a dimly lit podcast studio
Photo by Reza Tavakoli on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • We checked eight claims about BPC-157 from the Huberman Lab podcast episode with internal medicine physician Abud Bakri, published June 1, 2026, against FDA's own records, the World Anti-Doping Agency's list and the published studies, read on October 2 and re-read on October 27, 2026.
  • Six hold up. One date can't be checked on FDA's current record: the episode puts BPC-157's move into Category 2 in late 2024, and FDA's page now lists BPC-157 among withdrawn nominations with no date.
  • One claim can't be checked: that compounding pharmacies sell BPC-157 relabelled as pentadeca arginate. No published chemistry exists for a product by that name.
  • The episode's picture of the evidence is fair. A 2025 systematic review found 35 preclinical studies and one clinical study, and no clinical safety data.

How we checked

Peptide claims travel through clips, summaries and reposts, and each step loses detail. So we started from the source: the full transcript that Huberman Lab publishes with its episode "Peptides: The Science, Uses & Safety", in which Andrew Huberman interviews Dr. Abud Bakri, an internal medicine physician 1. Every claim below is attributed to the person the transcript shows saying it.

Each claim gets one of four verdicts: accurate; accurate, with a caveat; inaccurate; or can't be checked, when no source exists that could settle it. Every source was read on October 2, 2026 and re-read on October 27, 2026; the episode page notes that its transcript is under human review and may contain errors 1. We quote the episode once, where the exact words matter, and describe the other claims in our own words.

What the episode said about FDA

1. BPC-157 was never approved by FDA

Accurate. Bakri said BPC-157 never received FDA approval 1. FDA has never approved a drug containing it; the agency's own list of bulk substances that may present significant safety risks includes it 2. Our encyclopedia grades its evidence Low; the BPC-157 entry has the details.

2. It was moved into Category 2 in late 2024

Can't be checked on FDA's current record. In Bakri's words: "In late 2024, BPC 157 and 20 other peptides got moved" 1. FDA's page of substances that may present significant safety risks (content current as of April 22, 2026) now lists BPC-157 in a table of nominations withdrawn by the nominators, which has no date column; substances still in Category 2 on the same page, such as kisspeptin-10 and ibutamoren mesylate, carry a 503A date added of September 29, 2023 2. An earlier version of this article gave September 29, 2023 as BPC-157's own date; FDA's current page does not show that, so we no longer grade the claim. The page lists the agency's concerns about BPC-157: possible immune reactions for some routes of administration, difficulties with peptide-related impurities and with characterising the active ingredient, and little or no safety information for the proposed routes 2. We did not check the count of other peptides.

3. It came off Category 2 in April but is not in Category 1

Accurate, as far as the record shows, both when the episode aired and on October 27, 2026. Bakri said BPC-157 had been removed from Category 2 that April without being placed in Category 1, the list that would let pharmacies compound it under FDA's interim policy 1. FDA's current pages no longer carry the April notice: its Category 2 page (content current as of April 22, 2026) lists BPC-157 among nominations withdrawn by the nominators, without a date 2, and a law-firm report says FDA gave notice on April 15, 2026 that it would remove 12 peptides from Category 2 after seven days 3. Its category list, last updated May 14, 2026, names BPC-157 in none of its three categories 4, and as of October 27, 2026 no Federal Register document has added it to the 503A list 5.

4. The first review round would cover seven peptides

Accurate. Bakri predicted that FDA's first round of reconsideration would take up seven peptides, BPC-157 and TB-500 among them 1. On July 23 and 24, FDA's compounding advisory committee reviewed seven and recommended six for the 503A list, BPC-157 by 8 votes to 6, as reported by law firms; FDA has posted no tallies 6 7. A recommendation is advice, not a rule: as of October 27, 2026, BPC-157 was not on FDA's list 45.

On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of BPC-157, TB-500, MOTS-c, KPV, semax and epitalon under the forms, routes and conditions in its Appendix B 8. The policy is non-binding, labelled a draft and open to revision; FDA has not added any of them to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).

What the episode said about sport

5. BPC-157 is on WADA's list

Accurate. Bakri said BPC-157 is on the World Anti-Doping Agency's list 1. WADA's 2026 Prohibited List names it among the non-approved substances in class S0, which are prohibited at all times, and the 2027 list keeps the same wording 9. For athletes, that settles it whatever happens at FDA.

The claim about pentadeca arginate

6. Pharmacies relabel BPC-157 as pentadeca arginate

Can't be checked. Bakri said compounding pharmacies sell BPC-157 under the name PDA, or pentadeca arginate 1. We looked for anything that could confirm or refute what that product is. As of October 27, 2026, PubMed holds no paper naming pentadeca arginate or pentadecapeptide arginate, and on October 2 PubChem had no compound record under that name 10. Whether a product sold as pentadeca arginate contains BPC-157, a salt of it or something else could only be settled by testing samples, and we found no published test.

What the episode said about the evidence

7. There is far more animal data than human data

Accurate. Bakri said BPC-157 has a large animal literature and that "we just don't know when it comes to humans" 1. The most thorough summary we found is a 2025 systematic review in the HSS Journal: from 544 records it included 36 studies, of which 35 were preclinical and 1 was clinical, and it found no clinical safety data 11.

That one clinical study was a telephone survey of patients at a single hormone clinic in Florida, looking back at knee injections given in 2019 and 2020, four of them combined with thymosin beta-4. Of 16 patients reached, 14 reported relief, by the authors' own count; there was no control group and no specific tool to measure pain or function 12. The review summarised the same study as 7 of 12 patients reporting relief for more than six months 11. Since the review, a pilot study gave two adults intravenous infusions of 10 mg and then 20 mg and reported no changes in heart, liver, kidney, thyroid or glucose markers; both had used the peptide before, and there was no comparison group 13. Neither study had a control group.

8. Animal studies show no cancer signal

Accurate, with a caveat. Bakri said the animal literature shows no signal for cancer, and added that most of it comes from one research group, so it should be read carefully 1. The systematic review agrees on the first part: preclinical safety studies reported no adverse effects across several organ systems 11. The caveat is what those studies can show. With no clinical safety data at all 11, the absence of a signal in animals is not evidence of long-term safety in people. FDA's stated concerns are different again: immune reactions and product quality 2.

What we didn't check

BPC-157 also came up on a September 2026 episode of The Joe Rogan Experience with Huberman as a guest. The summaries of that conversation published online disagree with each other about what was described, and we found no transcript we could verify. So this article quotes none of them. When a claim reaches you through a clip or a summary, finding the full episode and the timestamp is the first check, and often the one that changes the story.

How to check a podcast claim yourself

Four checks catch most problems. First, go to the transcript or the full episode, not the clip. Second, check dates and statuses against the regulator's own record: FDA's page of substances with significant safety risks lists the date each substance still in Category 2 was added 2, and WADA publishes its list every year 9. Third, ask whether a study was in animals or people, how many people, and whether there was a control group. Fourth, ask whether the claim is still true: BPC-157 went into Category 2 and then left it 2 3, and a correct statement in June can be out of date by October.

Our BPC-157 and TB-500 Low entries keep the evidence and status for both peptides current, and our report on the July votes explains what the committee's recommendations do and don't change.

Frequently asked questions

What did the Huberman Lab peptides episode get right about BPC-157?

Of eight claims we checked, six hold up and two can't be checked on the current record: it was never FDA-approved, it came off Category 2 without entering Category 1 (FDA gives no date; a law-firm report dates FDA's notice to April 15, 2026), the first review round covered seven peptides, it is on WADA's list, animal data far outweigh human data, and animal studies show no cancer signal, with caveats.

When was BPC-157 put in FDA's Category 2?

FDA's current page (content current as of April 22, 2026) no longer shows a date for BPC-157, which it lists among nominations withdrawn by the nominators. Substances still in Category 2, such as kisspeptin-10, carry a 503A date of September 29, 2023. The episode said late 2024.

Is BPC-157 legal to compound now?

Not on the record as of October 27, 2026. FDA lists its Category 2 nomination as withdrawn but did not place it in Category 1, and although an advisory committee recommended it for the 503A list in July, no document has added it.

Are there human studies of BPC-157?

Very few. A 2025 systematic review found one clinical study among 36, a retrospective survey of 16 knee-injection patients; a two-person intravenous safety pilot followed. Neither had a control group.

Is BPC-157 banned in sport?

Yes. WADA's 2026 Prohibited List names it among the non-approved substances in class S0, prohibited at all times, and the 2027 list keeps it.

Sources

  1. Huberman Lab. Peptides: The Science, Uses & Safety, with Dr. Abud Bakri. Episode page and transcript (marked 'currently under human review and may contain errors'), hubermanlab.com, published June 1, 2026; read October 2 and October 27, 2026.
  2. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (fda.gov); Content current as of April 22, 2026; read October 27, 2026: BPC-157 listed under 'Bulk drug substances nominated but withdrawn' (no date column); Category 2 table gives kisspeptin-10 and ibutamoren mesylate a 503A date added of September 29, 2023.
  3. Orrick, Herrington & Sutcliffe. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings, April 16, 2026: FDA gave notice on April 15 that 'after 7 days, it will remove 12 peptide bulk drug substances from Category 2', nominations 'withdrawn by the nominators'; removal does not by itself place them on the 503A list or in Category 1. Read October 27, 2026. Cited without a link.
  4. US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list), updated May 14, 2026; read October 2 and October 27, 2026.
  5. Federal Register API: search for FDA documents on section 503A bulk drug substances published since July 1, 2026, none found; queried October 2 and October 27, 2026.
  6. McDermott (law firm). Bulk-list bound? PCAC backs majority of peptides in two-day public meeting (July 27, 2026): tallies for all seven. Read October 27, 2026; FDA has posted no minutes or tallies. Other reports agree on every tally except epitalon's 'no' count (7-4-1 here and in the FDA Law Blog; 7-5-1 in RAPS Regulatory Focus). Cited without a link.
  7. Grey Peptides. The July 2026 PCAC votes (/news/pcac-july-2026-votes/), September 25, 2026, from FDA's meeting materials and published meeting reports; FDA has posted no tallies.
  8. US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register
  9. World Anti-Doping Agency. The 2026 Prohibited List (in effect January 1, 2026) and the 2027 Prohibited List, class S0 (non-approved substances), prohibited at all times, which names BPC-157 among its examples. Read October 2, 2026; 2026 List re-read October 27, 2026. WADA
  10. Grey Peptides Registry (assets/registry.json): searches of PubMed and PubChem for pentadeca arginate, October 2, 2026, with no record found in either; PubMed re-searched October 27, 2026 for pentadeca arginate, pentadecapeptide arginate and BPC-157 arginate, none found.
  11. Vasireddi, N., Hahamyan, H., Salata, M. J., et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 21(4), 485-495. PMID: 40756949
  12. Lee, E., & Padgett, B. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine, 27(4), 8-13. PMID: 34324435
  13. Lee, E., & Burgess, K. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine, 31(5), 20-24. PMID: 40131143

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead